New oral sits at the center of this dementia and brain health question.
Despite the hopeful framing of this headline, the full picture requires an honest clarification: as of March 2026, no oral drug has yet received FDA approval for primary progressive multiple sclerosis. But we are closer than we have ever been. Fenebrutinib, an oral BTK inhibitor developed by Genentech and Roche, has now posted positive results across all three of its Phase III clinical trials — including the landmark FENtrepid study in 985 adults with PPMS, where it proved noninferior to ocrelizumab (Ocrevus), the only treatment approved for PPMS since March 28, 2017. Those results, which showed a 12 percent reduction in the risk of disability progression compared to the current standard of care, represent the first time in over a decade that an investigational medicine has moved the needle on progressive MS disability.
For the roughly 10 to 15 percent of MS patients diagnosed with the primary progressive form — where disability accumulates steadily without the relapses and remissions that characterize other types — this is not a small development. These patients have waited nearly nine years with only one approved therapy, one that requires either intravenous infusion or subcutaneous injection. An effective oral pill that can cross the blood-brain barrier would reshape how PPMS is managed day to day. This article examines what fenebrutinib’s Phase III data actually showed, why another oral BTK inhibitor failed in the same space, what the regulatory path forward looks like, and what patients and caregivers dealing with progressive MS should realistically expect in the months ahead.
Table of Contents
- What Is Fenebrutinib and Why Has an Oral Drug for Primary Progressive MS Taken Years in the Making?
- What the FENtrepid Phase III Trial Actually Showed — and Where the Limits Are
- Why Tolebrutinib Failed Where Fenebrutinib Succeeded
- What an Oral Treatment Would Mean in Practice for PPMS Patients
- The Regulatory Road Ahead and Why Approval Is Not Guaranteed
- What This Means for Brain Health Beyond MS
- What Patients and Caregivers Should Do Now
- Conclusion
- Frequently Asked Questions
What Is Fenebrutinib and Why Has an Oral Drug for Primary Progressive MS Taken Years in the Making?
Fenebrutinib belongs to a class of drugs called Bruton’s tyrosine kinase inhibitors, or BTK inhibitors. What makes this class different from existing MS treatments is where it works. Most current therapies for MS operate primarily in the peripheral immune system — they tamp down immune activity in the blood and lymph nodes. BTK inhibitors like fenebrutinib are brain-penetrant, meaning they can cross the blood-brain barrier and target inflammatory processes happening inside the central nervous system itself. Specifically, fenebrutinib acts on microglia and B cells that reside behind the barrier, cells increasingly believed to drive the smoldering neuroinflammation that characterizes progressive MS. This distinction matters because the biology of primary progressive MS has always been the core obstacle. Relapsing forms of MS involve discrete immune attacks that are relatively easier to suppress with peripheral immunotherapies. Progressive MS, by contrast, involves a slower, more diffuse process of neurodegeneration that existing drugs have struggled to reach.
When Ocrevus was approved in 2017, it was a genuine breakthrough — the first drug to show any benefit in PPMS at all. But ocrelizumab is a monoclonal antibody that depletes B cells in the blood; it does not readily penetrate the brain. The hypothesis behind BTK inhibitors is that treating the inflammation at its source, inside the brain, could offer benefits that peripheral B-cell depletion cannot fully achieve. The reason this has taken years is partly scientific and partly practical. Developing drugs for progressive MS requires long trials with large populations, because disability accumulation is slow and hard to measure over short timeframes. The FENtrepid trial enrolled 985 patients and required a minimum of 120 weeks of treatment — over two years — just to evaluate the primary endpoint. Clinical research on this scale, for a disease subtype that affects a smaller patient population, is expensive and slow. That it has finally yielded a positive result is significant precisely because so many prior attempts stalled or failed.
What the FENtrepid Phase III Trial Actually Showed — and Where the Limits Are
The FENtrepid trial was a randomized, double-blind study comparing fenebrutinib head-to-head against ocrelizumab in adults with PPMS. The primary endpoint was 12-week composite confirmed disability progression, and fenebrutinib met the bar for noninferiority — meaning it was statistically shown to be at least as effective as the existing standard of care. Beyond that threshold, the data showed a numerical 12 percent reduction in the risk of disability progression favoring fenebrutinib over ocrelizumab, with benefits observable as early as 24 weeks into treatment. One of the more striking secondary findings involved upper limb function. Fenebrutinib reduced worsening on the 9-hole peg test — a standard measure of hand and arm dexterity — by 26 percent compared to Ocrevus. For patients with progressive MS, where loss of hand function can mean the difference between independence and needing daily assistance with tasks like eating, dressing, or writing, this is a clinically meaningful result that goes beyond the headline disability numbers.
However, this trial was not without caveats. On the safety side, transient and reversible liver enzyme elevations occurred in 13.3 percent of patients on fenebrutinib, compared with 2.9 percent on ocrelizumab. While no cases met the threshold for Hy’s law — the benchmark for serious drug-induced liver injury — this is a signal that will require ongoing monitoring. Patients with pre-existing liver conditions or those taking other hepatotoxic medications may face additional considerations. It is also worth noting that the trial demonstrated noninferiority, not outright superiority. The 12 percent risk reduction is encouraging but was a numerical trend, and regulatory agencies will scrutinize whether this crosses the threshold for a superiority claim when the full data are presented at the AAN Annual Meeting in 2026.
Why Tolebrutinib Failed Where Fenebrutinib Succeeded
Fenebrutinib was not the only oral BTK inhibitor racing toward a PPMS indication. Tolebrutinib, developed by Sanofi, was tested in the PERSEUS Phase III trial with a similar goal: to delay disability progression in primary progressive MS. On December 15, 2025, Sanofi announced that PERSEUS did not meet its primary endpoint. Tolebrutinib failed to significantly delay the time to six-month composite confirmed disability progression compared to placebo in PPMS patients aged 18 to 55 with EDSS scores between 2.0 and 6.5. The failure was compounded by a separate regulatory setback. In December 2025, the FDA issued a Complete Response Letter rejecting tolebrutinib for non-relapsing secondary progressive MS, effectively closing that door as well.
Sanofi has stated it will not pursue regulatory approval for tolebrutinib in PPMS. There were some partial signals — MRI data showed fewer new brain lesions and slower brain volume loss in the tolebrutinib group — but these imaging benefits did not translate into the clinical disability endpoints that matter for approval. The divergent outcomes of these two drugs illustrate something important about BTK inhibitors as a class: they are not interchangeable. Differences in brain penetrance, selectivity for specific BTK-dependent pathways, dosing, and pharmacokinetics can all influence whether a given molecule reaches the right targets at the right concentrations. Fenebrutinib’s success does not validate the entire class for progressive MS; it validates fenebrutinib specifically. This is a useful reminder for patients and clinicians who may hear that “BTK inhibitors work in PPMS” — the accurate statement is that one BTK inhibitor has shown promising Phase III results, while another did not.
What an Oral Treatment Would Mean in Practice for PPMS Patients
For the past nine years, the only approved option for PPMS has been Ocrevus. The original formulation requires intravenous infusion, typically administered every six months in a clinical setting. In September 2024, Ocrevus Zunovo was approved as a subcutaneous injection alternative, which is faster to administer but still requires a healthcare setting and involves injection. Neither option is something a patient can manage independently at home with a pill and a glass of water. An oral, brain-penetrant drug like fenebrutinib would represent a fundamentally different treatment experience. Daily pill-taking is more familiar, less disruptive to daily life, and eliminates the need for infusion appointments that can take hours including observation time.
For patients in rural areas or those with mobility limitations — which is a large portion of the PPMS population — reducing the burden of treatment administration is not a minor quality-of-life improvement. It can determine whether someone stays on therapy at all. That said, the tradeoff is not purely in favor of oral dosing. Infusion-based therapies like Ocrevus are administered under medical supervision, which means side effects are observed in real time and doses are never missed accidentally. An oral daily medication requires consistent adherence, and the 13.3 percent rate of liver enzyme elevations with fenebrutinib means patients will likely need regular blood work to monitor liver function — a requirement that adds its own logistical burden. The choice between an oral BTK inhibitor and an infused monoclonal antibody, if both are eventually available, will involve weighing convenience against monitoring requirements, and that calculus will differ for every patient.
The Regulatory Road Ahead and Why Approval Is Not Guaranteed
Genentech and Roche now have three positive Phase III datasets in hand: FENtrepid for PPMS, FENhance 1 for relapsing MS (which showed a 51 percent reduction in annualized relapse rate versus teriflunomide over 96-plus weeks, announced March 2026), and FENhance 2, also positive for relapsing MS (announced November 2025). The companies have indicated that all three datasets will be submitted to regulatory authorities, with full data to be presented at the AAN Annual Meeting in 2026. But positive Phase III results do not automatically translate to FDA approval. The liver safety signal, while manageable in a clinical trial with close monitoring, will face scrutiny in the context of a broader real-world population. The FDA will evaluate whether the benefit-risk profile justifies approval, particularly given that the FENtrepid trial showed noninferiority rather than clear superiority over an existing approved therapy.
Regulatory agencies may also require a Risk Evaluation and Mitigation Strategy, or REMS, that mandates liver monitoring — which could affect how freely the drug is prescribed and how quickly it reaches patients. There is also the question of timeline. Even under priority review, FDA approval typically takes 6 to 12 months after submission. If Genentech submits in late 2026, approval might not come until 2027. Patients and caregivers hoping for an imminent oral option should understand that “years in the making” may still mean additional months or longer of waiting. And if safety concerns arise during the review — as they did with tolebrutinib — the timeline could extend further or result in additional requirements.
What This Means for Brain Health Beyond MS
The success of a brain-penetrant BTK inhibitor in progressive MS has implications that extend beyond the MS community. The mechanism of action — targeting microglia and resident immune cells inside the central nervous system — is relevant to other neurodegenerative conditions where neuroinflammation plays a role. Researchers studying Alzheimer’s disease, Parkinson’s disease, and other forms of dementia have increasingly focused on microglial activation as a driver of disease progression.
While fenebrutinib is being developed specifically for MS, the proof of concept that an oral drug can meaningfully modulate brain-resident immune activity is being watched closely across the neurodegeneration field. This does not mean fenebrutinib will be repurposed for dementia any time soon — the biology is different enough that separate trials would be needed. But for readers of a brain health site, the broader takeaway is that the pharmaceutical industry is getting better at designing small molecules that penetrate the blood-brain barrier and act on specific inflammatory pathways within the brain, a capability that was largely aspirational a decade ago.
What Patients and Caregivers Should Do Now
For people currently living with PPMS, the practical question is what to do between now and whenever fenebrutinib might become available. The honest answer is that Ocrevus remains the standard of care and the only approved option. Patients who are stable on Ocrevus should not discontinue treatment in anticipation of an oral alternative that has not yet been approved. Those who are newly diagnosed or considering starting treatment should discuss the current landscape with their neurologist, including whether participation in any ongoing or follow-up studies might be appropriate.
Looking forward, the convergence of three positive Phase III trials for fenebrutinib — spanning both relapsing and progressive MS — creates a compelling regulatory package. If approved, it would not only be the first oral treatment for PPMS but would offer a single medication that could potentially serve patients across multiple MS subtypes. That kind of versatility, combined with the convenience of oral dosing and the mechanistic advantage of brain penetrance, represents the most significant shift in progressive MS treatment since Ocrevus arrived in 2017. The years of waiting may finally be nearing their end — but they are not quite over yet.
Conclusion
Fenebrutinib’s positive Phase III results in primary progressive MS mark the most meaningful advance in this space in nearly a decade. The FENtrepid trial demonstrated that an oral, brain-penetrant BTK inhibitor can match and potentially exceed the efficacy of ocrelizumab, with particular benefits for upper limb function that matter in daily life. The failure of tolebrutinib in the same disease underscores that these results are specific to fenebrutinib, not a given for the drug class.
Regulatory submission is expected, with full data to be presented at the AAN Annual Meeting in 2026. Approval is plausible but not certain, and the timeline will depend on how regulators weigh the benefit-risk profile, particularly around liver safety monitoring. For now, patients and caregivers should stay informed, maintain current treatment plans, and have candid conversations with their neurologists about what the evolving landscape may mean for their individual care. The progress is real — but so is the distance still left to travel.
Frequently Asked Questions
Has an oral drug been approved for primary progressive MS?
No. As of March 2026, no oral drug has received FDA approval for PPMS. Ocrevus (ocrelizumab), an intravenous infusion approved in March 2017, and Ocrevus Zunovo, a subcutaneous injection approved in September 2024, remain the only approved treatments. Fenebrutinib is the leading oral candidate based on positive Phase III results, but it has not yet been submitted for or granted regulatory approval.
What is fenebrutinib and how does it differ from Ocrevus?
Fenebrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor that can cross the blood-brain barrier to target microglia and B cells inside the central nervous system. Ocrevus is a monoclonal antibody given by IV infusion that depletes B cells in the blood. The key difference is that fenebrutinib acts on inflammatory processes within the brain itself, while Ocrevus works primarily in the peripheral immune system.
What were the main results of the FENtrepid trial?
The FENtrepid trial enrolled 985 PPMS patients and found fenebrutinib noninferior to ocrelizumab in delaying disability progression, with a 12 percent reduction in disability progression risk. It also showed a 26 percent reduction in upper limb function worsening on the 9-hole peg test compared to Ocrevus.
Why did tolebrutinib fail in PPMS while fenebrutinib succeeded?
Tolebrutinib, another oral BTK inhibitor developed by Sanofi, did not meet its primary endpoint in the PERSEUS Phase III trial announced December 2025. While both drugs are BTK inhibitors, they differ in brain penetrance, selectivity, and pharmacokinetics. The divergent outcomes demonstrate that not all BTK inhibitors perform equally in progressive MS.
What are the safety concerns with fenebrutinib?
The main safety signal is liver enzyme elevations, which occurred in 13.3 percent of fenebrutinib patients compared to 2.9 percent on ocrelizumab in the FENtrepid trial. These elevations were transient and reversible, and no cases of serious drug-induced liver injury (Hy’s law cases) were observed. Regular liver function monitoring will likely be required.
When might fenebrutinib become available for PPMS patients?
Genentech and Roche plan to submit all three Phase III datasets to regulatory authorities, with full data presentation expected at the AAN Annual Meeting in 2026. Even under an expedited review, FDA approval could take 6 to 12 months after submission, meaning availability in 2027 at the earliest is a reasonable expectation.
You Might Also Like
- New Oral Testosterone Gets FDA Approval — Why This Is Different
- This Topical Drug Is Replacing Oral Antibiotics for Rosacea
- The Oral Thrombectomy Drug Showing Promise for Stroke
For more, see NIH MedlinePlus — cognitive testing.
